Cite
Vandergaast R, Carey T, Reiter S, et al. Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2. bioRxiv. 2020;doi: 10.1101/2020.05.26.117549.
Vandergaast, R., Carey, T., Reiter, S., Lech, P., Gnanadurai, C., Tesfay, M., Buehler, J., Suksanpaisan, L., Naik, S., Brunton, B., Recker, J., Haselton, M., Ziegler, C., Roesler, A., Mills, J. R., Theel, E., Weaver, S. C., Rafael, G., Roforth, M. M., Jerde, C., Tran, S., Diaz, R. M., Bexon, A., Baum, A., Kyratsous, C. A., Peng, K. W., & Russell, S. J. (2020). Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.05.26.117549
Vandergaast, Rianna, et al. "Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.05.26.117549
Vandergaast R, Carey T, Reiter S, Lech P, Gnanadurai C, Tesfay M, Buehler J, Suksanpaisan L, Naik S, Brunton B, Recker J, Haselton M, Ziegler C, Roesler A, Mills JR, Theel E, Weaver SC, Rafael G, Roforth MM, Jerde C, Tran S, Diaz RM, Bexon A, Baum A, Kyratsous CA, Peng KW, Russell SJ. Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting antibodies that neutralize SARS-CoV-2. bioRxiv. 2020 May 27; doi: 10.1101/2020.05.26.117549. PMID: 32577655; PMCID: PMC7302210.
Copy
Download .nbib